311 related articles for article (PubMed ID: 32731915)
1. A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.
Kim K; Yang WH; Jung YS; Cha JH
BMB Rep; 2020 Nov; 53(10):512-520. PubMed ID: 32731915
[TBL] [Abstract][Full Text] [Related]
2. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules.
Zhou G; Sprengers D; Mancham S; Erkens R; Boor PPC; van Beek AA; Doukas M; Noordam L; Campos Carrascosa L; de Ruiter V; van Leeuwen RWF; Polak WG; de Jonge J; Groot Koerkamp B; van Rosmalen B; van Gulik TM; Verheij J; IJzermans JNM; Bruno MJ; Kwekkeboom J
J Hepatol; 2019 Oct; 71(4):753-762. PubMed ID: 31195061
[TBL] [Abstract][Full Text] [Related]
3. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
Balta E; Wabnitz GH; Samstag Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
[TBL] [Abstract][Full Text] [Related]
4. Rationale for anti-CD137 cancer immunotherapy.
Makkouk A; Chester C; Kohrt HE
Eur J Cancer; 2016 Feb; 54():112-119. PubMed ID: 26751393
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression.
Saleh R; Elkord E
Semin Cancer Biol; 2020 Oct; 65():13-27. PubMed ID: 31362073
[TBL] [Abstract][Full Text] [Related]
6. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk.
Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E
JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464
[TBL] [Abstract][Full Text] [Related]
7. Immune-mediated anti-tumor effects of metformin; targeting metabolic reprogramming of T cells as a new possible mechanism for anti-cancer effects of metformin.
Bahrambeigi S; Shafiei-Irannejad V
Biochem Pharmacol; 2020 Apr; 174():113787. PubMed ID: 31884044
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of IL-15 on immune cells and its potential for the treatment of cancer.
Zhang S; Zhao J; Bai X; Handley M; Shan F
Int Immunopharmacol; 2021 Feb; 91():107318. PubMed ID: 33383444
[TBL] [Abstract][Full Text] [Related]
9. Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies.
Waibl Polania J; Lerner EC; Wilkinson DS; Hoyt-Miggelbrink A; Fecci PE
Front Immunol; 2021; 12():777073. PubMed ID: 34868044
[TBL] [Abstract][Full Text] [Related]
10. Metformin-containing hydrogel scaffold to augment CAR-T therapy against post-surgical solid tumors.
Chao Y; Wei T; Li Q; Liu B; Hao Y; Chen M; Wu Y; Song F; Chen Q; Liu Z
Biomaterials; 2023 Apr; 295():122052. PubMed ID: 36827893
[TBL] [Abstract][Full Text] [Related]
11. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
12. Immune-mediated antitumor effect by type 2 diabetes drug, metformin.
Eikawa S; Nishida M; Mizukami S; Yamazaki C; Nakayama E; Udono H
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1809-14. PubMed ID: 25624476
[TBL] [Abstract][Full Text] [Related]
13. Metformin Effects on FOXP3
Amin D; Richa T; Mollaee M; Zhan T; Tassone P; Johnson J; Luginbuhl A; Cognetti D; Martinez-Outschoorn U; Stapp R; Solomides C; Rodeck U; Curry J
Laryngoscope; 2020 Sep; 130(9):E490-E498. PubMed ID: 31593308
[TBL] [Abstract][Full Text] [Related]
14. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Duan J; Wang Y; Jiao S
Cancer Med; 2018 Sep; 7(9):4517-4529. PubMed ID: 30088347
[TBL] [Abstract][Full Text] [Related]
16. Metformin improves cancer immunotherapy by directly rescuing tumor-infiltrating CD8 T lymphocytes from hypoxia-induced immunosuppression.
Finisguerra V; Dvorakova T; Formenti M; Van Meerbeeck P; Mignion L; Gallez B; Van den Eynde BJ
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147018
[TBL] [Abstract][Full Text] [Related]
17. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
18. CD8
Farhood B; Najafi M; Mortezaee K
J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
[TBL] [Abstract][Full Text] [Related]
19. Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment.
Scarfò I; Maus MV
J Immunother Cancer; 2017; 5():28. PubMed ID: 28331617
[TBL] [Abstract][Full Text] [Related]
20. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
Martinez M; Moon EK
Front Immunol; 2019; 10():128. PubMed ID: 30804938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
